Quantum BioPharma (NASDAQ: QNTM) has entered into a Study Start-Up Agreement (SUA) with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-21-302 (Lucid-MS) for multiple sclerosis (MS). The agreement initiates formal study start-up activities following FDA clearance to proceed with the trial, according to a press release issued by NEWMEDIAWIRE. Thermo Fisher will support study start-up and related clinical research services through its PPD Clinical Research Business.
The randomized, double-blind, placebo-controlled Phase 2 trial will evaluate the efficacy, safety, and tolerability of Lucid-MS in people with progressive forms of MS using clinical and radiological endpoints. Lucid-MS is an investigational, first-in-class New Chemical Entity designed to provide neuroprotection by inhibiting demyelination through targeting protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation.
This development is significant for the MS community, as progressive forms of the disease currently have limited treatment options. If successful, Lucid-MS could become a novel therapy that addresses the underlying mechanism of myelin degradation, potentially slowing or reversing disability progression. The global MS market is substantial, with millions of patients worldwide, and a new treatment option could capture significant market share.
For investors, the agreement with Thermo Fisher, a leading clinical research organization, lends credibility to the trial's execution. Quantum BioPharma's shares could see increased attention as the trial progresses. The company is dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. Preclinical models have shown that Lucid-MS can prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis.
To view the full press release, visit https://ibn.fm/CZH9U. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM.
Quantum also invented UNBUZZD and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026. The agreement includes royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
Forward-looking statements in the press release note risks and uncertainties that could cause actual results to differ materially. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer.
